Allergy Therapeutics hits key safety milestone in peanut allergy study

Allergy Therapeutics said its PROTECT Phase I/IIa peanut allergy trial met its primary safety endpoint after the highest planned dose was completed and proved safe and well tolerated in the minimum required cohort; the early-stage study dosed 48 volunteers and raised exposure up to 2,000-fold from the starting level without safety concerns. Earlier cohorts showed pharmacodynamic signs of effect—reduced skin-prick wheal size, suppressed basophil activation and rising Ara h2 IgG—and blinded biomarker readings three months post-dosing in allergic participants suggest a sustained response, while healthy participant data support the proposed mechanism. The programme will move into unblinded skin-prick testing and up to one-year safety follow-up, with a second interim analysis on the highest doses due in Q1 2026 and Phase IIb preparations underway to set dosing based on these safety and efficacy signals, reinforcing management's confidence in the short-course VLP Peanut approach.

Analysis

Allergy Therapeutics PLC reported that its PROTECT Phase I/IIa peanut allergy trial met the primary safety endpoint after completing dosing at the highest planned level; the cohort included 48 volunteers and exposure was raised up to 2,000-fold from the starting dose without triggering safety concerns. The company describes VLP Peanut as a short-course immunotherapy intended to retrain the immune response, and management framed the outcome as a regulatory milestone with CEO Manuel Llobet citing reinforced confidence in the approach.

Earlier lower-dose cohorts produced pharmacodynamic signals consistent with biological activity: reductions in skin‑prick wheal size, suppressed basophil activation and rising Ara h2 IgG protective antibodies, and healthy participant data supported the proposed mechanism. Preliminary blinded biomarker readings taken three months after the last dose in allergic participants point to a sustained response, though these are early and limited signals.

The programme moves to unblinded skin‑prick testing and up to one year of safety follow-up, with a second interim analysis on the highest doses due in Q1 2026 and Phase IIb preparations underway to set dosing using current safety/efficacy signals. The safety milestone materially de‑risks tolerability but leaves efficacy durability and larger‑cohort performance unresolved; sentiment is mildly positive (score 0.35) and market impact modest (0.32), consistent with early‑stage clinical validation rather than commercial clarity.

Key Decisions for Investors

• Consider a limited, speculative position sized to your risk tolerance to capture upside from the upcoming Q1 2026 interim analysis while acknowledging early-stage clinical risk
• Monitor the second interim analysis, the forthcoming unblinded skin-prick results and the one-year safety follow-up as the primary near-term catalysts before increasing exposure
• Defer meaningful position increases until Phase IIb dosing decisions and corroborating efficacy signals in larger cohorts are announced
• Employ tight position sizing or hedges given that safety is addressed but efficacy durability and broader tolerability remain unproven